These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 3493074

  • 1. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. II. Lyt-1+2- T cells have potential to reject antigenically irrelevant (bystander) tumor cells on activation with the specific target tumor cells.
    Yoshioka T, Fujiwara H, Takai Y, Ogata M, Shimizu J, Hamaoka T.
    Cancer Immunol Immunother; 1987; 24(1):8-12. PubMed ID: 3493074
    [Abstract] [Full Text] [Related]

  • 2. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T.
    J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
    [Abstract] [Full Text] [Related]

  • 3. Requirements of adherent cells for activating Lyt-1+2- T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt-1+2- T cells.
    Sakamoto K, Fujiwara H, Nakajima H, Yoshioka T, Takai Y, Hamaoka T.
    Jpn J Cancer Res; 1986 Nov; 77(11):1142-52. PubMed ID: 3098724
    [Abstract] [Full Text] [Related]

  • 4. Mechanisms for recognition of tumor antigens and mediation of anti-tumor effect by noncytolytic Lyt-2+ T cell subset.
    Sakamoto K, Yoshioka T, Shimizu J, Sato S, Nakajima H, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1988 Jan; 79(1):99-108. PubMed ID: 3128511
    [Abstract] [Full Text] [Related]

  • 5. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.
    Fujiwara H, Takai Y, Sakamoto K, Hamaoka T.
    J Immunol; 1985 Sep; 135(3):2187-91. PubMed ID: 3874911
    [Abstract] [Full Text] [Related]

  • 6. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
    Tomita S, Fujiwara H, Yamane Y, Sano S, Nakajima H, Izumi Y, Arai H, Kawanishi Y, Tsuchida T, Hamaoka T.
    Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830
    [Abstract] [Full Text] [Related]

  • 7. The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo.
    Yoshioka T, Fukuzawa M, Takai Y, Wakamiya N, Ueda S, Kato S, Fujiwara H, Hamaoka T.
    Cancer Immunol Immunother; 1986 Feb; 21(3):193-8. PubMed ID: 2938736
    [Abstract] [Full Text] [Related]

  • 8. Effector cell analysis of tumor cell rejection in vivo in two syngeneic tumor systems exhibiting distinct in vitro cytotoxic mechanisms.
    Fukuzawa M, Fujiwara H, Yoshioka T, Itoh K, Hamaoka T.
    Gan; 1984 Oct; 75(10):912-9. PubMed ID: 6334626
    [Abstract] [Full Text] [Related]

  • 9. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
    Nakajima H, Fujiwara H, Takai Y, Izumi Y, Sano S, Tsuchida T, Hamaoka T.
    J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
    [Abstract] [Full Text] [Related]

  • 10. Studies on macrophage-activating factor (MAF) in antitumor immune responses. II. Molecular characterization of MAF produced by the tumor-immune Lyt-1+2- T cell subset.
    Nakajima H, Izumi Y, Sugihara S, Satoh Y, Isumi S, Gotoh T, Fujiwara H, Hamaoka T.
    Cancer Immunol Immunother; 1987 Sep; 25(3):201-8. PubMed ID: 3119213
    [Abstract] [Full Text] [Related]

  • 11. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers.
    Suda T, Fujiwara H, Mizushima Y, Shearer GM, Hamaoka T.
    J Natl Cancer Inst; 1986 Dec; 77(6):1267-72. PubMed ID: 2948049
    [Abstract] [Full Text] [Related]

  • 12. Enhanced induction of tumor-specific Lyt-1+2- T cell-mediated protective immunity by in vivo administration of interleukin 1.
    Izumi Y, Tsuchida T, Okuno K, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1985 Sep; 76(9):863-70. PubMed ID: 3932286
    [Abstract] [Full Text] [Related]

  • 13. Differential ability of tumor-unique and cross-reactive antigen(s) on two murine hepatoma cell lines to induce Lyt-1+2- T cells responsible for in vivo protective immunity.
    Shima J, Yoshioka T, Kosugi A, Ogata M, Fujiwara H, Hamaoka T, Ueda S, Kato S.
    Biken J; 1987 Mar; 30(1):1-8. PubMed ID: 2445335
    [Abstract] [Full Text] [Related]

  • 14. Mediation of in vivo tumor-neutralizing activity by Lyt-2+ as well as L3T4+ T cell subsets.
    Yoshioka T, Sato S, Ogata M, Sakamoto K, Sano H, Shima J, Yamamoto H, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1988 Jan; 79(1):91-8. PubMed ID: 2965692
    [Abstract] [Full Text] [Related]

  • 15. Selective suppression of the generation of anti-tumor L3T4+ but not of Lyt-2+ T cell-mediated immunity in the tumor-bearing state.
    Sano H, Sato S, Shima J, Tada T, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1988 Jul; 79(7):857-65. PubMed ID: 3139599
    [Abstract] [Full Text] [Related]

  • 16. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
    Fujiwara H, Yoshioka T, Shima J, Kosugi A, Itoh K, Hamaoka T.
    J Immunol; 1986 Apr 01; 136(7):2715-9. PubMed ID: 3005417
    [Abstract] [Full Text] [Related]

  • 17. The activation of L3T4+ helper T cells assisting the generation of anti-tumor Lyt-2+ cytotoxic T lymphocytes: requirement of Ia-positive antigen-presenting cells for processing and presentation of tumor antigens.
    Kosugi A, Yoshioka T, Suda T, Sano H, Takahama Y, Fujiwara H, Hamaoka T.
    J Leukoc Biol; 1987 Dec 01; 42(6):632-41. PubMed ID: 2960766
    [Abstract] [Full Text] [Related]

  • 18. Suppressive effect of portal venous inoculation with tumor cells on the anti-tumor immune potential.
    Kokudo S, Qian JH, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1987 Sep 01; 78(9):946-51. PubMed ID: 3117751
    [Abstract] [Full Text] [Related]

  • 19. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
    Barker E, Wise JA, Dray S, Mokyr MB.
    Cancer Res; 1989 Sep 15; 49(18):5007-15. PubMed ID: 2788494
    [Abstract] [Full Text] [Related]

  • 20. Additional evidence for the augmented induction of tumor-specific resistance in vaccinia virus-primed mice by immunization with vaccinia virus-modulated syngeneic tumor cells.
    Ueda S, Wakamiya N, Wu KS, Kato S, Fujiwara H, Hamaoka T.
    Biken J; 1984 Mar 15; 27(1):1-7. PubMed ID: 6385960
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.